Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University
• Treatments: Butyric Acid; Cortisol succinate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Hydrocortisone-17-butyrate

Criteria

Inclusion Criteria:

• Male or female ≥ 18 years of age.

• Subjects must have diagnosis of mild to moderate atopic dermatitis using IGA criteria. (2 or 3 on severity scale)

• Subjects must have >5% TBSA and <30% to be enrolled.

• Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.

Exclusion Criteria:

• Known allergy or sensitivity to topical Locoid® cream, ointment or lipocream in the subject.

• Inability to complete all study-related visits.

• Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study.

• Requiring >130 gm of cream in a 2 week period.

• Having facial or groin involvement of their disease.

• Pregnant women and women who are breast feeding are to be excluded. Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.